Format

Send to

Choose Destination
Bone Marrow Transplant. 2019 Feb 6. doi: 10.1038/s41409-019-0465-9. [Epub ahead of print]

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Author information

1
EBMT Activity Survey Office, Hematology, Department of Medicine, University Hospital, Basel, Switzerland. jakob.passweg@usb.ch.
2
EBMT Activity Survey Office, Hematology, Department of Medicine, University Hospital, Basel, Switzerland.
3
Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
4
Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.
5
Pediatric Hematology, Oncology and Stem Cell Transplantation Department, Children's Hospital, Regensburg, Germany.
6
Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.
7
Department of Haematology, University Medical Centre, Utrecht, The Netherlands.
8
BMT Centre, Leiden University Medical Centre Leiden, Leiden, The Netherlands.
9
St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
10
BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.
11
Sheffield Teaching Hospitals NHS Foundation, Royal Hallamshire Hospital, Sheffield, UK.
12
Pediatric Hematology and Oncology, University Hospital, Collegium Medicum UMK, Bydgoszcz, Poland.
13
CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France.
14
Hematopoietic SCT Unit, Florence Nightingale Sisli Hospital, Istanbul, Turkey.
15
Department of Hematology, Hospital Saint Antoine, Paris, France.
16
Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.

Abstract

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.

PMID:
30728439
DOI:
10.1038/s41409-019-0465-9

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center